Alkem Laboratories launches 'Empanorm' medicine in India

12 Mar 2025 Evaluate

Alkem Laboratories has launched generic empagliflozin and its combinations in India under the brand name ‘Empanorm’ at prices that are around 80% lower than the innovator products. Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicted for use in the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD) and chronic heart failure (HF). The company’s generic empagliflozin and its combinations are bioequivalent to innovator products. 

Keeping patient-convenience in mind, the company is offering the medicine in a considerably smaller tablet size than the innovator products. The company’s generic empagliflozin is available under the brand name ‘Empanorm’ and its combinations namely empagliflozin and linagliptin is available under the name ‘Empanorm L’; empagliflozin and sitagliptin is available under the name ‘Empanorm Duo’ and ‘Alsita E’; and empagliflozin and metformin is available under the name ‘Empanorm M’.

Alkem Laboratories is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.

Alkem Laboratories Share Price

4704.10 -46.25 (-0.97%)
13-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1683.85
Dr. Reddys Lab 1107.85
Cipla 1461.60
Lupin 1969.05
Zydus Lifesciences 882.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...